Development of the Glaucoma Visual Functioning Questionnaire-40 and Its Psychometric Properties
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04722861 |
|
Recruitment Status : Unknown
Verified January 2021 by Zhongshan Ophthalmic Center, Sun Yat-sen University.
Recruitment status was: Enrolling by invitation
First Posted : January 25, 2021
Last Update Posted : January 25, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment |
|---|---|
| Primary Glaucoma Glaucoma Suspect | Other: GVFQ-40 |
Glaucoma is the leading cause of irreversible blindness in the world. It is estimated that by 2040, the number of glaucoma patients in the world's population aged 40-80 will exceed 110 million [1]. As a chronic progressive blindness disease, glaucoma can seriously damage visual function such as visual acuity, visual field and contrast sensitivity, restrict patients' daily life activities and leads to a serious decline in vision-related quality of life (VRQOL) and health-related quality of life (HRQOL) [2-5]. Comprehensive evaluation of the visual function of glaucoma patients can not only educate the impact of glaucoma, but also reflect the effect of clinical treatment or rehabilitation interventions. However, the objective testing methods commonly used in clinic, such as visual acuity, visual field and contrast sensitivity, can only be used to evaluate part of the visual function of patients, which can not reflect the impact of disease and corresponding interventions from the point of view of patients. The use of patient defined measures of vision function in ophthalmic assessment and treatment evaluation is now well accepted and a number of questionnaires have been developed, such as NEI VFQ-25, LVQOL and SF-36, which mostly focus on investigating VRQOL or HRQOL[6-10]. There are comparatively few vision function questionnaires developed to measure the visual ability for glaucoma patients. The objective of this study is to develop and test the psychometric properties of a self-report questionaire, the Glaucoma Visual Functioning Questionnaire-40 (GVFQ-40), which was designed to measure the difficulty of daily activities of glaucoma patients and evaluate the effectiveness of clinical treatment or rehabilitation interventions.
The GVFQ-40 consists of 40 items and measures the impact of glaucoma on restriction of participation in daily activities in five domains of functioning (mobility, visual tracking, reading, identification and night vision ). Each item has six answer options, that is, no difficulty (score = 1), mild difficulty (score = 2), moderate difficulty (score = 3), extremely difficult (score = 4), completely unable to complete (score = 5), and do not performed for nonvisual reasons (no score).
| Study Type : | Observational |
| Estimated Enrollment : | 400 participants |
| Observational Model: | Case-Control |
| Time Perspective: | Cross-Sectional |
| Official Title: | Development of the Glaucoma Visual Functioning Questionnaire-40 and Its Psychometric Properties |
| Actual Study Start Date : | September 8, 2020 |
| Estimated Primary Completion Date : | April 30, 2021 |
| Estimated Study Completion Date : | May 30, 2021 |
| Group/Cohort | Intervention/treatment |
|---|---|
|
Primary Glaucoma
Patients with primary glaucoma diagnosed by glaucoma professionals
|
Other: GVFQ-40
GVFQ-40 is a 40-item questionnaire developed to evaluate the visual ability of glaucoma patients in detail. It consists of 40 items and measures the impact of glaucoma on restriction of participation in daily activities in five domains of functioning. Each item is rated on a five-level scale from ''no difficulty'' to ''can't do because of vision''. Another possible response is that the activity is not performed for nonvisual reasons. |
|
Glaucoma Suspect Controls
Glaucoma suspect controls had a diagnosis of glaucoma suspect or ocular hypertension, and also were required to have a presenting Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity of 20/40 or better in both eyes.
|
Other: GVFQ-40
GVFQ-40 is a 40-item questionnaire developed to evaluate the visual ability of glaucoma patients in detail. It consists of 40 items and measures the impact of glaucoma on restriction of participation in daily activities in five domains of functioning. Each item is rated on a five-level scale from ''no difficulty'' to ''can't do because of vision''. Another possible response is that the activity is not performed for nonvisual reasons. |
- GVFQ-40 [ Time Frame: 1 day (Only once) ]GVFQ-40 is a 40-item questionnaire developed to evaluate the visual ability of glaucoma patients in detail. It consists of 40 items and measures the impact of glaucoma on restriction of participation in daily activities in five domains of functioning. Each item is rated on a five-level scale from ''no difficulty'' to ''can't do because of vision''. Another possible response is that the activity is not performed for nonvisual reasons. The GVFQ-40 is administered by a trained interviewer to all enrolled participants. A subset of participants (35 subjects) will complete the GVFQ-40 twice 2 to 3 weeks apart.
- Diagnosis and treatment information of ophthalmopathy [ Time Frame: 1 day (Only once) ]The diagnosis and treatment information of ophthalmopathy, such as disease diagnosis name, time, history of drug treatment and history of operation, were obtained from the hospital electronic medical record system or outpatient medical record data.
- NEI VFQ-25 [ Time Frame: 1 day (Only once) ]The National Eye Institute-Visual Function Questionnaire-25 (NEI VFQ-25) is a valid and reliable VRQOL questionnaire designed for persons who have chronic eye diseases or low vision.
- ETDRS visual acuity [ Time Frame: 1 day (Only once) ]The information of ETDRS visual acuity was obtained from the hospital electronic medical record system or outpatient medical record data.
- Intraocular pressure [ Time Frame: 1 day (Only once) ]The information of intraocular pressure was obtained from the hospital electronic medical record system or outpatient medical record data.
- Automatic perimetry report [ Time Frame: 1 day (Only once) ]Automatic perimetry reports were obtained from the hospital electronic medical record system or outpatient medical record data.
- Pelli-Robson contrast sensitivity [ Time Frame: 1 day (Only once) ]Pelli-Robson contrast sensitivity test card was used.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
- Primary glaucoma: patients with primary glaucoma diagnosed by glaucoma professionals
- Glaucoma Suspect Controls: glaucoma suspect controls had a diagnosis of glaucoma suspect or ocular hypertension, and also were required to have a presenting Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity of 20/40 or better in both eyes.
Inclusion Criteria:
1.1 Inclusion criteria of primary glaucoma group:
- age ≥ 18 years old;
- being able to express clearly and cooperate with the investigators;
- diagnosed with primary glaucoma;
- complete clinical data.
1.2 Inclusion criteria of glaucoma suspect controls:
- age ≥ 18 years old;
- being able to express clearly and cooperate with the investigators;
- diagnosed with glaucoma suspect or ocular hypertension;
- having a presenting Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity of 20/40 or better in both eyes;
- complete clinical data.
Exclusion Criteria:
1.1 Exclusion criteria for primary glaucoma group:
- serious cognitive dysfunction, psychological dysfunction, or hearing impairment;
- physical motor dysfunction, hyperthyroidism or hypothyroidism, malignant tumors and other serious systemic diseases;
- complicated with other ophthalmopathy affecting visual function (except cataract, ametropia), such as age-related macular degeneration, diabetic retinopathy, optic nerve disease, retinal vascular disease, etc;
- surgical intervention (incisional or laser) within 2 weeks of the date of completing questionnaires (before or after);
- not complete the questionnaire.
1.2 Exclusion criteria for glaucoma suspect controls:
- serious cognitive dysfunction, psychological dysfunction, or hearing impairment;
- physical motor dysfunction, hyperthyroidism or hypothyroidism, malignant tumors and other serious systemic diseases;
- complicated with other ophthalmopathy affecting visual function (except cataract, ametropia), such as age-related macular degeneration, diabetic retinopathy, optic nerve disease, retinal vascular disease, etc;
- not complete the questionnaire.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04722861
| China, Guangdong | |
| Zhongshan Ophthalmic Center, Sun Yat-sen University | |
| Guangzhou, Guangdong, China, 510060 | |
Publications of Results:
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Zhongshan Ophthalmic Center, Sun Yat-sen University |
| ClinicalTrials.gov Identifier: | NCT04722861 |
| Other Study ID Numbers: |
2020KYPJ186 |
| First Posted: | January 25, 2021 Key Record Dates |
| Last Update Posted: | January 25, 2021 |
| Last Verified: | January 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Glaucoma Ocular Hypertension Eye Diseases |